Zai Lab

Yahoo Finance • 8 days ago

Zai Lab announces departure of President and COO Josh Smiley

Biotech firm Zai Lab (ZLAB [https://seekingalpha.com/symbol/ZLAB]) announced that President and COO Josh Smiley is leaving the company [https://seekingalpha.com/pr/20525617-zai-lab-announces-changes-to-senior-leadership-team] immediately a... Full story

Yahoo Finance • 19 days ago

Zai Lab wins FDA fast track status for cancer drug zocilurtatug pelitecan

Zai Lab (ZLAB [https://seekingalpha.com/symbol/ZLAB]) said the U.S. FDA granted fast track designation to its experimental cancer drug zocilurtatug pelitecan for treating extrapulmonary neuroendocrine carcinomas after standard first-line t... Full story

Yahoo Finance • 19 days ago

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need - Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a fi... Full story

Yahoo Finance • 22 days ago

Zai Lab expects Zoci Phase III enrollment completion in first half of 2027, while targeting first FDA BLA in late 2027

Earnings Call Insights: Zai Lab (ZLAB) Q1 2026 MANAGEMENT VIEW * CEO Ying Du framed the quarter as an inflection in global development, saying, "Zai Lab is at a pivotal moment," and linked the strategy to global execution and productiv... Full story

Yahoo Finance • 23 days ago

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

– Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for VYVGART – Zocilurtatug pel... Full story

Yahoo Finance • last month

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combinatio... Full story

Yahoo Finance • 2 months ago

JPMorgan Cuts PT on Zai Lab Limited (ZLAB) to $32 From $39 – Here’s Why

Zai Lab Limited (NASDAQ:ZLAB) is one of the best high growth healthcare stocks to buy now. JPMorgan cut the price target on Zai Lab Limited (NASDAQ:ZLAB) to $32 from $39 on March 18, reiterating an Overweight rating on the shares. The rati... Full story

Yahoo Finance • 3 months ago

Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising Incidence and Advancements in Targeted Therapies | DelveInsight

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies are expanding treatment options and boosting... Full story

Yahoo Finance • 3 months ago

Is Zai Lab (ZLAB) Now A Bargain After Recent 15.8% Share Price Jump?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether Zai Lab's current share price reflects its true worth, you are not alone. Many investors... Full story

Yahoo Finance • 3 months ago

Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028

Earnings Call Insights: Zai Lab (ZLAB) Q4 2025 MANAGEMENT VIEW * Ying Du, Founder, Chairperson & CEO, highlighted that Zai Lab is at a pivotal moment, stating the company is "building a company increasingly defined by global innovation... Full story

Yahoo Finance • 3 months ago

Zai Lab GAAP EPS of -$0.05 beats by $0.30, revenue of $127.6M beats by $4.93M

* Zai Lab press release [https://seekingalpha.com/pr/20414959-zai-lab-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate] (ZLAB [https://seekingalpha.com/symbol/ZLAB]): Q4 GAAP EPS of -$0.05 beats by $0.30... Full story

Yahoo Finance • 4 months ago

China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse.

U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the rivalry? Continue Reading... Full story

Yahoo Finance • 4 months ago

Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

Asian equities traded in the US as American depositary receipts were trending lower Tuesday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

Zai Lab Receives Approval In China For Schizophrenia Drug COBENFY

(RTTNews) - Zai Lab Limited (ZLAB) today announced that China's National Medical Products Administration (NMPA) has approved COBENFY for the treatment of schizophrenia in adults. Schizophrenia is a chronic and disabling mental health diso... Full story

Yahoo Finance • 6 months ago

Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat

Asian equities traded in the US as American depositary receipts were tracking lower Friday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 9 months ago

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

Biotech stocks Zai Labs and BeOne Medicines plummeted Wednesday on reports President Donald Trump will issue an executive order to reduce U.S. access to drugs developed in China. Continue Reading View Comments... Full story

Yahoo Finance • 9 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB

NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB).  Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • 9 months ago

Jefferies assumes coverage on Zai Lab stock with Buy rating, $52 price target

Investing.com - Jefferies has assumed coverage on Zai Lab (NASDAQ:ZLAB) with a Buy rating and a price target of $52.00. The company, currently valued at approximately $4 billion, has seen its shares trade between $17.50 and $44.34 over t... Full story

Yahoo Finance • 10 months ago

Zai Lab Q2 2025 Earnings Preview

* Zai Lab (NASDAQ:ZLAB [https://seekingalpha.com/symbol/ZLAB]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is -$0.42 [https://seekingalpha.com/symbol/ZLAB/earni... Full story

Yahoo Finance • 10 months ago

AstraZeneca succeeds in late-stage trial for myasthenia gravis therapy

[Prime Minister Scott Morrison Announces Deal With AstraZeneca To Supply Potential COVID-19 Vaccine] Lisa Maree Williams/Getty Images News AstraZeneca (NASDAQ:AZN [https://seekingalpha.com/symbol/AZN]) announced Thursday that gefurulimab,... Full story